Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis

This study explores the efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease (IBD) through a meta-analysis.

A comprehensive search encompassed randomised controlled trials examining the efficacy of etrolizumab in the treatment of IBD in PubMed, Embase, the Cochrane Library and Web of Science, with a search cut-off date of 1 December 2023. Quality assessment was based on the Cochrane Manual's risk of bias assessment, while Stata 15 undertook the data analysis.

Five randomised controlled trials involving 1,682 individuals were finally included. The results of the meta-analysis suggest that, compared with placebo, etrolizumab may improve clinical response (RR = 1.26, 95% CI [1.04-1.51]), clinical remission (RR = 1.26, 95% CI [1.04-1.51]) and endoscopic relief (RR = 2.10, 95% CI [1.56-2.82]) in patients with IBD, endoscopic improvement (RR = 2.10, 95% CI [1.56-2.82]), endoscopic remission (RR = 2.10, 95% CI [1.56-2.82], histological remission (RR = 1.62, 95% CI [1, 26-2.08]), with no increase in adverse events (RR = 0.95, 95% CI [0.90-1.01]) or serious adverse events (RR = 0.94, 95% CI [0.68-1.31]).

According to this study, etrolizumab is a promising drug for IBD.